Current Report Filing (8-k)
29 October 2021 - 11:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October
29, 2021
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State or Other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
1185 Avenue of the Americas, Third Floor, New York, New York
|
|
10036
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
844-967-2633
(Registrant’s telephone number, including area
code)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.012
|
|
ORMP
|
|
The Nasdaq Capital Market, Tel Aviv Stock Exchange
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On October 29, 2021, Oramed Pharmaceuticals
Inc. (the “Company”) announced that its majority-owned subsidiary, Oravax Medical Inc., has received clearance from the South
African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral
COVID-19 vaccine and preparations to begin the trials are now underway.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
|
|
|
October 29, 2021
|
|
|
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Jul 2023 to Jul 2024